JP7265620B2 - 強皮症の治療のための方法 - Google Patents

強皮症の治療のための方法 Download PDF

Info

Publication number
JP7265620B2
JP7265620B2 JP2021518472A JP2021518472A JP7265620B2 JP 7265620 B2 JP7265620 B2 JP 7265620B2 JP 2021518472 A JP2021518472 A JP 2021518472A JP 2021518472 A JP2021518472 A JP 2021518472A JP 7265620 B2 JP7265620 B2 JP 7265620B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
hydrate
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518472A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020072824A5 (enExample
JP2022504181A (ja
Inventor
ジョン ダブリュー． アダムス，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68290393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7265620(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022504181A publication Critical patent/JP2022504181A/ja
Publication of JPWO2020072824A5 publication Critical patent/JPWO2020072824A5/ja
Priority to JP2023055658A priority Critical patent/JP2023082117A/ja
Application granted granted Critical
Publication of JP7265620B2 publication Critical patent/JP7265620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021518472A 2018-10-03 2019-10-03 強皮症の治療のための方法 Active JP7265620B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023055658A JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740855P 2018-10-03 2018-10-03
US62/740,855 2018-10-03
PCT/US2019/054576 WO2020072824A1 (en) 2018-10-03 2019-10-03 Methods for the treatment of scleroderma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023055658A Division JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Publications (3)

Publication Number Publication Date
JP2022504181A JP2022504181A (ja) 2022-01-13
JPWO2020072824A5 JPWO2020072824A5 (enExample) 2022-09-29
JP7265620B2 true JP7265620B2 (ja) 2023-04-26

Family

ID=68290393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518472A Active JP7265620B2 (ja) 2018-10-03 2019-10-03 強皮症の治療のための方法
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Country Status (5)

Country Link
US (1) US20210386706A1 (enExample)
EP (1) EP3860590B1 (enExample)
JP (2) JP7265620B2 (enExample)
ES (1) ES2951870T3 (enExample)
WO (1) WO2020072824A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2018525336A (ja) 2015-06-22 2018-09-06 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US11478448B2 (en) * 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
BR112020024762A2 (pt) * 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
CA3124701A1 (en) * 2019-01-08 2020-07-16 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2018525336A (ja) 2015-06-22 2018-09-06 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Therapeutic Patents，2016年，Vol.26, No.4, pp.455-470

Also Published As

Publication number Publication date
EP3860590A1 (en) 2021-08-11
JP2023082117A (ja) 2023-06-13
EP3860590B1 (en) 2023-06-07
ES2951870T3 (es) 2023-10-25
JP2022504181A (ja) 2022-01-13
US20210386706A1 (en) 2021-12-16
WO2020072824A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
JP7265620B2 (ja) 強皮症の治療のための方法
US12097182B2 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) Compounds and methods for treatment of primary biliary cholangitis
JP6441267B2 (ja) 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
US20110237682A1 (en) S1p receptor modulators for treating mutiple sclerosis
JPWO2003006019A1 (ja) 間質性膀胱炎治療用医薬組成物
AU2020327022B2 (en) Method of treating cancer
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
JP2013544870A (ja) 肝障害のリスク管理に使用する薬剤の調製のためのドロネダロンの使用
EP2694074B1 (en) Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
KR20200062240A (ko) 시포니모드의 투여 요법
HK40057784A (en) Etrasimod for use in methods for the treatment of scleroderma
HK40057784B (en) Etrasimod for use in methods for the treatment of scleroderma
US20230404979A1 (en) Alpha-2 adrenergic receptor agonists to reduce mortality and improve outcomes in viral respiratory syndromes
JP4551649B2 (ja) 血管透過性亢進抑制剤
US20250302798A1 (en) Sting inhibitors and use thereof
US20070054838A1 (en) Method for improving diagnostic quality in echocardiography
HK40019900B (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
HK40019900A (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EA049014B1 (ru) Способ лечения рака

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230414

R150 Certificate of patent or registration of utility model

Ref document number: 7265620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150